Maxim analyst Anthony Vendetti raised the firm’s price target on SeaStar Medical (ICU) to $8 from $6 and keeps a Buy rating on the shares. The company’s Q1 revenue, gross margin, and gap loss per share were all above estimates, the analyst tells investors in a research note. Maxim is raising its 2026 and 2027 revenue estimates for SeaStar but also widening its loss per share outlook due to higher expected operating expense, the firm added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU: